Owlstone Medical

07/10/2025

📣 We are excited to announce that Owlstone Medical has been awarded up to $49.1M from ARPA-H for our project within the POSEIDON program, a groundbreaking initiative to develop the first at-home multi-cancer early detection test (MCED).

Throughout this program, we are proud to collaborate with Massachusetts Institute of Technology, Boston University, Georgia Tech Research, Qurin, and Planned Systems International.

Why does it matter? Nearly 40% of Americans will face cancer in their lifetime. Detecting it early not only saves lives but could also reduce healthcare costs by trillions of dollars.

Learn more about this development in our latest press release 👉 https://bit.ly/4nvM7YW

26/08/2025

We are recruiting for a Clinical Biomarker Scientist, if you have experience with biomarker science, data interpretation, and ensuring alignment of scientific capabilities with commercial needs, this role could be a great fit for you.

Find out more about the role and apply via our website: https://bit.ly/4n4f39P

12/08/2025

We are super excited to let you know about our new eBook: “Hydrogen Methane Breath Tests: The Complete Guide.”

The Guide is a one-stop shop for everything you need to know about breath tests in regards to your gut health and covers:

- The history of gut health and breath research
- The science of a Hydrogen Methane Breath Test (HMBT)
- Taking an HMBT
- Why an HMBT is an important step for those with digestive health concerns
- Longitudinal monitoring of Hydrogen and Methane

The eBook joins our other popular titles:

- The Gut-Skin Connection
- IBS
- Food Intolerances
- SIBO
- Low FODMAP certified Recipes

https://omedhealth.com/hmbt-ebook/

24/07/2025

We are recruiting for a Principal Project Manager, if you have experience with project and team leadership, project ex*****on, cross-functional coordination and stakeholder engagement, this role could be a great fit for you.

Find out more about the role and apply via out website: https://bit.ly/4lHbaap

02/06/2025

We are super excited to share details on OMED Health Inside Insights - a simple breath test to help you understand how lifestyle and environment may influence your gut, metabolic and lung health.

We don’t just test — we help you understand what it means. You’ll receive expert interpretation of your results, along with clear, personalised advice on how to support and improve your health.

Our first clinics will open in London and Cambridge soon and if you express your interest today you will be eligible for a discount on the test price of £399.

https://bit.ly/3StC1dl

Join us at OMED Health in Cambridge to discover what your breath reveals about your gut microbiome. Get a detailed report with insights into your microbial health.

27/01/2025

Ovarian cancer is the sixth most common cancer worldwide among women in developed countries and the ninth in developing countries.🌐

Symptoms can occur at all stages of ovarian cancer; however, they are usually nonspecific and can also occur in females without ovarian cancer.

📑 A study investigated the possibility of easily and non-invasively detecting and discriminating females with ovarian cancer from females that have no tumors and from females that have benign ge***al tract neoplasia, using exhaled breath samples.

Analysis of breath samples found that decanal, nonanal, styrene, 2-butanone, and hexadecane could serve as potential volatile markers for ovarian cancer.🌬️

Find out more about this research in our new case study where we discuss the methodologies and results from this paper in more detail: https://ow.ly/9w8Q50UBgXi

25/01/2025

Did you know that you can take part in a clinical study to help research to develop breath tests for diseases?

🤸If you are aged between 18-60, and are healthy as per medical records and interested in taking part, email us to get involved.

👉 [email protected]

Owlstone Medical are developing a breathalyser for disease.
Our Mission: To save 100,000 lives and $1.5B in healthcare costs. Our Vision: The global leader in Breath Biopsy for early detection and precision medicine.👨‍🔬

24/01/2025

We’re delighted to see a comment from our CEO Billy Boyle featured in the article: What Does 2025 Hold for Biopharma?

Billy gave his comments alongside 40 other industry experts, stating that “Breath analysis offers a non-invasive, rapid, and versatile tool for early disease diagnosis and treatment monitoring, improving patient outcomes”, and expanded on the future of our VOC Atlas project and expectations for 2025.

Read the full article here: https://ow.ly/mTFH50ULNFe

#2025

24/01/2025

Meet Dr Max Allsworth, Chief Science Officer.

Max is the Chief Science Officer at Owlstone Medical and has over 15 years experience in the development of trace chemical detection technologies. He has developed sensor technologies for a vast range of applications including personal safety, food contamination and environmental monitoring. At Owlstone he is responsible for the technical development of the breath capture devices and the analytical techniques behind biomarker identification. He has pioneered the development and application of Owlstone’s unique technologies to detect traces of chemicals in complex environments and at ever lower concentrations.

Learn more about Max here 👇
https://www.owlstonemedical.com/about/team/max-allsworth/

23/01/2025

📑 We recently published a paper, 'Development of a new breath collection method for analyzing volatile organic compounds from intubated mouse models', which you can view here: https://ow.ly/jVBb50UrSJG

In our new case study, we detail the new method for collecting breath from intubated mice and cover the results from this paper.

472 compounds were found in mouse breath, with 49 common compounds identified between mouse and human breath.🌬️

These compounds were linked to suspected biological functions, such as gut microbiota metabolism.

Read our case study here: https://ow.ly/eemq50UrSJF

22/01/2025

Meet Roxy Toma, Learning and Development Coordinator. Find out more about what Roxy does in her role and how she is helping us achieve our mission to save 100,000 lives and $1.5B in healthcare costs.

22/01/2025

Introducing Owlstone Medical - transforming healthcare for all using Breath Biopsy®.🌬️

At Owlstone, we are on a mission to save 100,000 lives and reduce healthcare costs by revolutionizing disease diagnosis and treatment.

Our Breath Biopsy technology provides a non-invasive way to identify disease-specific biomarkers in exhaled breath, unlocking new possibilities for earlier and more accurate diagnosis and treatment.👨‍⚕️

Did you know that the air we breath out contains information about our health? By analyzing volatile organic compounds (VOCs) in exhaled breath, we can detect conditions such as cancer, liver disease, and asthma at their earliest stages.

Early disease detection not only improves patient outcomes but also reduces the financial burden on healthcare systems worldwide.💰

We are working towards a future where non-invasive breath tests are an integral part of healthcare, enabling early and precise diagnosis, personalized treatment plans, and more effective disease monitoring.💪

Through our collaborations with leading healthcare organizations and pharmaceutical companies, including the Bill and Melinda Gates Foundation and the Food and Drug Administration (FDA), we are striving to make a difference with breath analysis.

Join us on the journey toward revolutionizing healthcare. Head over to our website to discover more: https://ow.ly/tbMe50UIyjj

Have any questions for us? Please leave them below or send us a message and our experts will be in touch.